TrialFrontiers in immunology2026

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Derrick Robertson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.